Copy link
Export CSV
Cite this view
HANK Price Transparency. (n.d.).
Tremelimumab-actl 300 MG/15ML Soln 15 mL Vial (NDC 310453530) by State .
PPMan price-transparency data, derived from CMS-required hospital MRFs.
Retrieved October 30, 2026 , from http://ppman.hank.ai/transparency/procedure/310453530/by-state?code_type=NDC
“Tremelimumab-actl 300 MG/15ML Soln 15 mL Vial (NDC 310453530) by State.” HANK Price Transparency ,
http://ppman.hank.ai/transparency/procedure/310453530/by-state?code_type=NDC. Accessed
October 30, 2026 .
“Tremelimumab-actl 300 MG/15ML Soln 15 mL Vial (NDC 310453530) by State,” HANK Price Transparency ,
accessed October 30, 2026 ,
http://ppman.hank.ai/transparency/procedure/310453530/by-state?code_type=NDC.
Source: PPMan price-transparency data, derived from CMS-required hospital
machine-readable files (45 CFR 180). See
methodology .
Print / Save PDF
NDC · across United States
310453530 — Tremelimumab-actl 300 Mg/15ml Soln 15 Ml Vial
State-by-state median negotiated rates. Lower bars are cheaper states; the
range bar shows the IQR (25th to 75th percentile within each state).
$81,011
National median
$60,556 – $192,152
IQR (p25 – p75)
3
hospitals filing
3
states
Walking in without insurance?
Cash / self-pay price
Cash median
$54,600
vs. negotiated
-32.6%
Hospitals reporting
15
Cash / self-pay rates apply when you don't run the bill through insurance.
Many hospitals also offer income-based discounts on top of the published
cash price — always ask about a financial-assistance application
before paying.
Median negotiated rate, by state
Ranked by typical (median) negotiated price. Hover for state-level IQR.
Median negotiated rate by state for 310453530 (NDC), with interquartile range
State Median p25 p75
NJ $245,685 $108,566 $446,637
OH $71,736 $60,556 $76,860
NY $57,330 $54,600 $92,820